Skip to main content

Table 1 Basal characteristics one year prior to or at index date of (A) all patients with mild to moderate and severe asthma and (B) after exclusion of patients with a COPD diagnosis (J44). Study population and sex are given as number and proportions (%) of patients and other data are given as mean values (standard deviation, SD). P-values indicate differences between mild to moderate and severe asthma in each group, respectively

From: Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR)

  A B
All patients (n = 18,724) Asthma only (no COPD) (n = 16,703)
Mild to moderate Severe P value Mild to moderate Severe P value
Study population, n (%) 17,934 (95.8) 790 (4.2) <0.001 16,142 (96.6) 561 (3,4) <0.001
Female, n (%) 11,293 (63.0) 472 (59.7) 0.071 10,157 (62.9) 337 (60.1) 0.169
Age at index 48.8 (19.2) 56.9 (16.9) <0.001 46.6 (18.6) 52.3 (16.8) <0.001
Age at death (years) 78.0 (13.2) 81.0 (8.6) 0.042 77.2 (15.1) 81.0 (10.2) 0.165
BMI (kg/m2)a 27.6 (6.0) 27.9 (5.8) 0.274 27.6 (6.0) 28.0 (5.6) 0.248
FEV1% predicted value post bronchodilationb 83.6 (21.1) 67.5 (25.9) <0.001 89.7 (15.9) 80.0 (22.1) 0.003
FVC % predicted value post bronchodilationb 94.7 (18.6) 84.3 (21.1) <0.001 97.7 (16.5) 91.1 (19.8) 0.043
FEV1/FVCb 0.737 (0.138) 0.640 (0.175) <0.001 0.777 (0.097) 0.715 (0.140) 0.005
Eosinophilsc, ×103 cells/μL 0.32 (0.43) 0.40 (0.63) 0.065 0.31 (0.44) 0.37 (0.43) 0.132
  1. aBMI was available in 53.0% of patients with mild to moderate asthma and 58.2% with severe asthma
  2. bAvailable data (<10% of the patients in both groups) from lung function measurements performed during the year prior to index date in both groups
  3. cData on blood eosinophilia was available in 16.8% of patients with mild to moderate asthma and 23.8% with severe asthma